A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

Completed · Phase 2 · Has a placebo group

Conditions studied: Fatty Liver

In brief

The purpose of this study is to evaluate the dietary supplement Siliphos, which comes from milk thistle, to determine whether it is safe and well-tolerated in adults who have non-alcoholic steatohepatitis (NASH). An additional aim of this study is to determine whether Siliphos may be beneficial in treatment of NASH as indicated by improvement in liver enzymes (ALT and AST). The study hypothesis is that Siliphos will be safe and well-tolerated in people with NASH and will result in a decrease in the liver enzymes ALT and AST.

Key facts

Study ID

NCT00443079

Run by

Heather Patton

People needed

6

Starts

2007-03-01

Expected to finish

2009-12-01

Last updated by the study team

2021-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Liver biopsy within 12 months demonstrating NASH
• Abnormal ALT

You may not qualify if…

• Uncontrolled diabetes
• Hepatitis B, hepatitis C, or other chronic liver conditions
• Abnormal kidney function
• Excess alcohol consumption

Where it is running

• University of California, San Diego Medical Center — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.